FDA approves Emcitate for peripheral thyrotoxicosis in patients with MCT8 deficiency

The U.S. Food and Drug Administration announced approval of Emcitate (tiratricol) tablets formulated for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also called Allan-Herndon-Dudley syndrome.

The decision represents the first FDA-cleared therapy aimed at the symptoms of this rare genetic disorder, which mainly affects males and stems from a faulty MCT8 transporter that prevents thyroid hormone from entering the brain while allowing excess hormone to accumulate in the blood.

FDA officials emphasized the agency’s dedication to rare diseases, noting that before this approval patients and families had no approved treatment options.

Emcitate is expected to alleviate cardiovascular and metabolic effects of high thyroid hormone levels, though it does not address the underlying brain hormone deficiency.